Teva’s generic label not skinny enough to protect from $234M damages to GSK August 6, 2021 Auto Bot BioPharma, biopharma nl, Biosimilars, generics, GSK, Legal, Pharma, Policy 0 When is a skinny label skinny enough to protect a generic drug from claims of patent infringement? The answer remains up to interpretation after an important, controversial decision from the Federal Circuit.